SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,495.95 |
| Enterprise Value ($M) | 1,422.20 |
| Book Value ($M) | 1,012.47 |
| Book Value / Share | 17.11 |
| Price / Book | 1.48 |
| NCAV ($M) | 985.04 |
| NCAV / Share | 16.65 |
| Price / NCAV | 1.52 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.08 |
| Return on Assets (ROA) | -0.11 |
| Return on Equity (ROE) | -0.12 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 58.47 |
| Current Ratio | 58.47 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 1,023.34 |
| Assets | 1,050.77 |
| Liabilities | 38.30 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 10.59 |
| Operating Income | -98.85 |
| Net Income | -68.99 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -43.81 |
| Cash from Investing | -258.02 |
| Cash from Financing | 713.24 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Ra Capital Management, L.p. | 19.90 | 14.63 | |
| 13G | Janus Henderson Group Plc | 6.10 | 93.84 | |
| 13G/A | Paradigm Biocapital Advisors LP | 6.00 | 34.79 | |
| 13G | Adage Capital Management, L.P. | 5.31 | ||
| 13G/A | Campbell David Alan | 4.80 | 3.91 | |
| 13G/A | Citadel Advisors Llc | 2.00 | ||
| 13G/A | Biotechnology Value Fund L P | 0.00 | -100.00 | |
| 13G/A | Fmr Llc | 15.00 | 67.51 | |
| 13D/A | Avalon Ventures XI, L.P. | 4.10 | -47.52 | |
| 13G/A | Bregua Corp | 5.80 | -21.68 | |
| 13D/A | Orbimed Advisors Llc | 3.80 | -25.82 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 166,303 | 1,142,482 | 14.56 | |
| 169,173 | 1,322,878 | 12.79 | |
| 110,279 | 650,193 | 16.96 | |
| 308,159 | 1,203,705 | 25.60 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| ITOS – iTeos Therapeutics, Inc. | IVVD – Invivyd, Inc. |
| IXHL – Incannex Healthcare Inc. | KALV – KalVista Pharmaceuticals, Inc. |
| KLTO – Klotho Neurosciences, Inc. |
Financial data and stock pages provided by
Fintel.io